Aquaculture Vaccines Market to Reach USD 4.2 Bn by 2031 as mRNA and Oral Vaccines Replace Antibiotics

[Hyderabad, April 17th, 2025] – The Aquaculture Vaccines Market, valued at 1.8 billion in 2023, will grow at 11.2% to 4.2 billion by 2031, as fish farms adopt advanced immunization, reports ClearView Market Insights.

Request Sample @ https://clearviewmarketinsights.com/report-details/global-aquaculture-vaccines-market/

2024 Industry Milestones

1. mRNA Breakthroughs

   • Elanco's water-delivered mRNA vaccine prevents 95% of TiLV cases.

   • RNAi-based shrimp vaccines enter commercial trials.

2. Needle-Free Revolution

   • PHARMAQ's oral vaccine survives digestive acids to trigger immunity.

   • Yeast-vectored vaccines provide 3x longer protection.

3. Climate Adaptation

   • Thermostable vaccines withstand 30°C without refrigeration.

   • Saline-tolerant formulations work across water types.

Regional Leaders

• Europe (40%): Norway vaccinates 100% of farmed salmon.

• Asia-Pacific (XX%): Vietnam's shrimp vaccine mandate.

• Americas (XX%): Chile's USD 1B+ vaccinated salmon industry.

Executive Insights
"We're vaccinating fish more precisely than humans now – with mRNA and oral tech."
– Jeff Simmons, CEO, Elanco

Roadmap to 2031

• 2025: 50% of shrimp farms transition from antibiotics to vaccines.

• 2027: mRNA vaccines cover 30% of salmon production.

• 2030: Universal fish vaccines targeting multiple pathogens expected.

For more insights, visit https://clearviewmarketinsights.com/report-store

About ClearView Market Insights

ClearView Market Insights analyzes more than 80 animal health markets, spanning from livestock to aquaculture.

Media contact:

Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.comPhone: +1 917-993-7369